​

REGENXBIO (RGNX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RGNX Stock Forecast

REGENXBIO (RGNX) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $25.33, with a high of $30.00 and a low of $22.00. This represents a 326.43% increase from the last price of $5.94.

$5 $10 $15 $20 $25 $30 High: $30 Avg: $25.33 Low: $22 Last Closed Price: $5.94

RGNX Stock Rating

REGENXBIO stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 1 Strong Buy (5.26%), 13 Buy (68.42%), 5 Hold (26.32%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 5 13 1 Strong Sell Sell Hold Buy Strong Buy

RGNX Price Target Upside V Benchmarks

TypeNameUpside
StockREGENXBIO326.43%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts118
Avg Price Target$24.00$24.00$31.13
Last Closing Price$5.94$5.94$5.94
Upside/Downside304.04%304.04%424.07%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25561--12
Mar, 25561--12
Feb, 2556---11
Jan, 2556---11
Dec, 24661--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 18, 2025Leerink Partners$24.00$7.80207.69%304.04%
Jan 07, 2025Luca IssiRBC Capital$30.00$8.36258.85%405.05%
Nov 15, 2024Judah FrommerMorgan Stanley$22.00$11.1497.49%270.37%
Oct 10, 2024Danielle BrillRaymond James$18.00$9.1995.87%203.03%
Sep 05, 2024Yi ChenH.C. Wainwright$39.00$11.38242.71%556.57%
Jun 24, 2024Annabel SamimyStifel Nicolaus$40.00$12.79212.74%573.40%
Jun 07, 2024Paul ChoiGoldman Sachs$38.00$13.76176.16%539.73%
May 15, 2024Yi ChenH.C. Wainwright$38.00$15.80140.51%539.73%
Mar 11, 2024Yi ChenH.C. Wainwright$36.00$22.8557.55%506.06%
Mar 08, 2024Luca IssiRBC Capital$35.00$22.7553.85%489.23%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 07, 2025RBC CapitalOutperformOutperformhold
Nov 18, 2024Raymond JamesOutperformOutperformhold
Oct 10, 2024Raymond JamesBuyBuyhold
Sep 04, 2024H.C. WainwrightBuyBuyhold
Aug 05, 2024Goldman SachsUnderperformUnderperformhold
Aug 05, 2024H.C. WainwrightBuyBuyhold
Jun 20, 2024RBC CapitalOutperformOutperformhold
Jun 07, 2024H.C. WainwrightBuyBuyhold
Jun 07, 2024Goldman SachsBuyinitialise
May 15, 2024WedbushBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.98$3.01$-6.50$-6.02$-4.59----
Avg Forecast$-2.85$3.89$-6.19$-5.52$-4.72$-0.48$-2.20$-2.54$-0.33
High Forecast$-2.01$5.38$-4.39$-2.61$-4.62$0.03$-0.56$-1.53$-0.24
Low Forecast$-3.94$2.74$-8.95$-6.31$-4.79$-1.24$-4.65$-3.55$-0.49
Surprise %4.56%-22.62%5.01%9.06%-2.75%----

Revenue Forecast

$50M $210M $370M $530M $690M $850M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$154.57M$470.35M$112.72M$90.24M$83.33M----
Avg Forecast$159.42M$492.16M$120.42M$118.32M$86.88M$321.48M$206.30M$391.55M$582.13M
High Forecast$206.22M$636.65M$161.77M$158.67M$89.69M$383.49M$212.22M$391.58M$800.54M
Low Forecast$123.01M$379.75M$93.43M$99.84M$79.03M$268.89M$200.38M$391.51M$466.03M
Surprise %-3.04%-4.43%-6.39%-23.73%-4.09%----

Net Income Forecast

$-350M $-230M $-110M $10M $130M $250M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-111.25M$127.84M$-280.32M$-263.49M$-227.10M----
Avg Forecast$-124.77M$170.21M$-155.31M$-263.49M$-205.87M$38.66K$-109.25M$-111.08M$-14.43M
High Forecast$-87.72M$235.18M$-124.25M$-210.80M$-202.25M$1.49M$-24.30M$-67.11M$-10.69M
Low Forecast$-172.39M$119.67M$-186.37M$-316.19M$-209.49M$-54.20M$-203.32M$-155.06M$-21.47M
Surprise %-10.83%-24.89%80.49%-10.31%----

RGNX Forecast FAQ

Is REGENXBIO stock a buy?

REGENXBIO stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 13 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that REGENXBIO is a favorable investment for most analysts.

What is REGENXBIO's price target?

REGENXBIO's price target, set by 19 Wall Street analysts, averages $25.33 over the next 12 months. The price target range spans from $22 at the low end to $30 at the high end, suggesting a potential 326.43% change from the previous closing price of $5.94.

How does REGENXBIO stock forecast compare to its benchmarks?

REGENXBIO's stock forecast shows a 326.43% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for REGENXBIO over the past three months?

  • April 2025: 41.67% Strong Buy, 50.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 41.67% Strong Buy, 50.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 45.45% Strong Buy, 54.55% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is REGENXBIO’s EPS forecast?

REGENXBIO's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.48, marking a -89.54% decrease from the reported $-4.59 in 2024. Estimates for the following years are $-2.2 in 2026, $-2.54 in 2027, and $-0.33 in 2028.

What is REGENXBIO’s revenue forecast?

REGENXBIO's average annual revenue forecast for its fiscal year ending in December 2025 is $321.48M, reflecting a 285.80% increase from the reported $83.33M in 2024. The forecast for 2026 is $206.3M, followed by $391.55M for 2027, and $582.14M for 2028.

What is REGENXBIO’s net income forecast?

REGENXBIO's net income forecast for the fiscal year ending in December 2025 stands at $38.66K, representing a -100.02% decrease from the reported $-227M in 2024. Projections indicate $-109M in 2026, $-111M in 2027, and $-14.432M in 2028.